Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in million yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In Japan, sales declined due to lower sales of Abbott products and restraint in purchases of locally sourced products. Selling, general and administrative expenses increased due to measures addressing wage increases and other factors. Meanwhile, overseas sales grew by double digits in yen terms.
No applicable matters. The notes on the going concern assumption state that there are no applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | 47,405 million yen (YoY -5.2%) |
| Operating profit | -983 million yen |
| Ordinary income | -339 million yen |
| Profit attributable to owners of the parent | -756 million yen |
| Net income per share | △¥4.73 |
| Equity ratio | End of the current fiscal period 72 / End of previous period 70.1 |
| Total assets | 246,158 million yen |
| Net assets | 177,291 million yen |
| Cash flows from operating activities | 8,141 million yen |
| Cash flows from investing activities | -328 million yen |
| Cash flows from financing activities | -3,193 million yen |
| Cash and cash equivalents at end of period | 50,630 million yen |
| Full-year earnings forecast | Net Sales 232,500 million yen (YoY -1.1%) / Operating profit 23,500 million yen (YoY +25.4%) / Ordinary income 23,500 million yen (YoY +4.2%) / Profit attributable to owners of the parent 15,000 million yen (YoY +3.4%) |
| Annual Dividend Forecast | 32 yen → 33 yen |
| Segment revenue | Japan 26,147 million yen (YoY -15.4%), North America 13,107 million yen (YoY +11.2%), Other regions 8,150 million yen (YoY +11.1%) |
| Segment profit | Japan 243 million yen (YoY -84.2%), North America -292 million yen, Other regions 46 million yen |
| Regional sales | 26,080 million yen (YoY -15.0%), 21,325 million yen (YoY +10.3%), 11,684 million yen (YoY +6.1%), 968 million yen (YoY -5.6%), 3,857 million yen (YoY +32.1%), 4,814 million yen (YoY +10.1%) |
| Depreciation and amortization | 1,281 million yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets 30 million yen / Extraordinary loss Loss on sale of fixed assets 0 million yen, Loss on Disposal of Fixed Assets 2 million yen |
| Disclosure regarding the going concern assumption | No applicable matters. The notes on the going concern assumption state that there are no applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | The Company disposed of 60,195 treasury shares as restricted stock compensation, and the payment procedures were completed on 31 July 2026. The total disposal amount was ¥90,292,500. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for securities analysts and institutional investors) |
| Issued Shares at Period-End | 167,961,960 Shares |
| Treasury Shares at Period-End | 7,989,554 Shares |
| Factors Behind Changes in Business Performance | In Japan, sales declined due to lower sales of Abbott products and restraint in purchases of locally sourced products. Selling, general and administrative expenses increased due to measures addressing wage increases and other factors. Meanwhile, overseas sales grew by double digits in yen terms. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In Japan, sales declined due to lower sales of Abbott products and restrained purchases of locally sourced products, while selling, general and administrative expenses increased, mainly due to measures addressing wage increases. Overseas sales increased, and for the full year the Company expects a recovery in capital investment by medical institutions and benefits from company-wide profitability reforms.